Clin Mol Hepatol.  2020 Oct;26(4):430-443. 10.3350/cmh.2020.0137.

Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

• Kim KS
• Lee BW

• KMID: 2507961
• DOI: http://doi.org/10.3350/cmh.2020.0137

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder and is associated with various metabolic diseases, including type 2 diabetes mellitus. There are no approved drugs for NAFLD, and the only approved treatment option is weight reduction. As insulin resistance plays an important role in the development of NAFLD, many anti-diabetic drugs have been evaluated for the treatment of NAFLD. Improvement of liver enzymes has been demonstrated by many anti-diabetic drugs, but histological assessment still remains insufficient. Pioglitazone could become the first-line therapy for T2DM patients with NAFLD, based on evidence of histological improvement in patients with biopsy-proven nonalcoholic steatohepatitis (NASH). Liraglutide, another promising alternative, is not yet recommended in patients with NAFLD/NASH due to limited evidence. Therefore, well-designed randomized controlled trials should be performed in the near future to demonstrate if and how anti-diabetic drugs can play a role in the treatment of NAFLD.

Keyword

Anti-diabetic drug; Diabetes mellitus; Metabolic diseases; Non-alcoholic fatty liver disease; Treatment